Genedata forms Japanese cancer diagnostic pact:
This article was originally published in Clinica
Executive Summary
Swiss firm Genedata has entered into a proteomics research collaboration with Japan's National Cancer Centre (NCC) that could lead to new diagnostic markers for cancer. NCC will use the Basel-based firm's Impressionist software to analyse the vast amounts of 2D-protein gel data generated from a range of different cancer types. As well as generating new targets for therapy and prevention, the partners hope to find marker proteins that will indicate the subclass of cancer.